Topics

Oligodendroglioma | Overall management | Overview

Home > Publications > Topics > Oligodendroglioma > Overall management > Overview

Sasaki H, Kitamura Y, Toda M, Hirose Y, Yoshida K.
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.
Brain Tumor Pathol. 2024 Apr 2. doi: 10.1007/s10014-024-00480-1. PMID: 38564040. Review˰ ˍ

Jiang K, Kalluri A, Odonkor M, Heinemann DM, Weber-Levine C, Raj D, Materi J, Rakovec M, Pineda E, Redmond KJ, Romo C, Kamson DO, Holdhoff M, Schreck KC, González Sánchez JJ, Bettegowda C, Rincon-Torroella J.
Trends in the Management of Oligodendrogliomas: A Multinational and Multidisciplinary Survey Study.
World Neurosurg. 2025 Feb 11:123716? doi: 10.1016/j.wneu.2025.123716? PMID: 39947316. Observational study˰ ˍ

Bertucci A, Dufour O, Appay R, Harlay V, Ducray F, Bronnimann C, Djelad A, Cohen-Jonathan Moyal E, Campone M, Langlois O, Ducloie M, Vauleon E, Younan N, Desenclos C, Ramirez C, Touat M, Idbaih A, Bequet C, Figarella-Branger D, Dehais C, Chinot O, Tabouret E; POLA network.
Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network study.
Cancer. 2025 Mar 30;131(7):e35814. doi: 10.1002/cncr.35814. PMID: 40159303. Observational study. ˍ